ALKS Q4 2021 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$324M+15.9% YoY

Gross Profit

$271M83.5% margin

Operating Income

$2M0.7% margin

Net Income

$873,0000.3% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

+10.3%

Cash Flow

Operating Cash Flow

$31M

Free Cash Flow

$22M

Stock-Based Comp.

$19M

Balance Sheet

Total Assets

$2.0B

Total Liabilities

$912M

Stockholders' Equity

$1.1B

Cash & Equivalents

$338M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$324M	$280M	+15.9%
Gross Profit	$271M	$237M	+14.2%
Operating Income	$2M	-$31M	+107.8%
Net Income	$873,000	-$43M	+102.0%

Revenue Segments

Product

$179M51%

Vivitrol

$92M26%

Aristada And Aristada Initio

$79M22%